Cancer jab can eradicate entire tumours in patients, trial shows A new triple-action cancer jab, amivantamab, has demonstrated unprecedented efficacy in an international trial, eradicating tumours in 15 out of 102 patients with advanced head and neck cancer and shrinking them in over a third overall. The injection targets cancer by blocking growth-promoting proteins and immune evasion pathways, while also activating the immune system. This treatment offers a more convenient subcutaneous administration compared to intravenous drips and has shown promising results in other cancers like lung cancer.

• Amivantamab, a triple-action cancer jab, has shown unprecedented results in an international trial, eradicating tumours in 15 patients and shrinking them in over a third.
• The trial involved 102 patients with advanced head and neck cancer whose disease had become resistant to other treatments.
• Amivantamab works by blocking EGFR and MET pathways and activating the immune system to attack tumours.
• The jab is administered subcutaneously, making it quicker and more convenient for patients compared to intravenous treatments.
• Patients like Carl Walsh experienced significant improvement in quality of life, with reduced swelling, pain, and a return to a normal diet and speech.
• Researchers highlighted the significance of the results in patients with HPV-negative head and neck cancers, which are typically harder to treat.
• Amivantamab is also being evaluated in clinical trials for lung, colorectal, brain, and gastric cancers.